Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients

NCT00952822 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT00952822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00952822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1
Overall status
Completed
Start date
August 8, 2008
Completion date
October 23, 2009
Enrollment
52 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a